About Us | Regen BioPharma, Inc

​"Putting together the brightest minds involved in basic science, drug development, medical practice and commercialization to develop new cures in the most rapid means possible."
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

For more information on the company, click here to request information.

​Areas of interest to the Company include:

  • Hematopoiesis (Blood formation)
  • Breast Cancer
  • Liver Cancer
  • Leukemia
  • Myelodysplastic Syndrome
  • Aplastic Anemia